Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the Editor

Asymptomatic and symptomatic respiratory virus infection detected in naso-pharyngeal swabs from solid organ transplant recipients early after transplantation

Keywords:
- Respiratory virus infection
- Solid organ transplant patients
- Immunosuppression

In transplant recipients, respiratory viral infections (RVI) are associated with high rates of morbidity and mortality. Although recent reports have underlined the increasing importance of RVI in solid organ transplant (SOT) recipients, little is known about its incidence early after transplantation. Immunosuppressive regimens impair SOT recipients' immune system disabling the protection against infections. In fact, viral pneumonias represent up to 20% of the causes of death among SOT recipients. We have characterized the incidence of RVI in SOT recipients during the first month post-transplantation using new molecular techniques. Since no virus (es) is associated with one specific syndrome, the identification of RV may be useful for an appropriate infection control and surveillance practices. We performed a prospective study enrolling ninety-eight SOT patients from February 2009 to February 2010. RVI was tested by multiplex-PCR (mPCR; Seeplex-RV12ACE Detection kit, Seegene Inc.) that detects 12 RV (human metapneumovirus, adenovirus, coronavirus 229E/NL63 and parainfluenza 1–3, rhinovirus A/B, coronavirus–OC43/HKU1, respiratory syncytial A–B and influenza A–B). During the first month after SOT the incidence of RVI was relevant at 31.6% (Table 1). Only 5 of these patients (16.1%) were symptomatic, while the rest of patients (26 patients, 83.9%) had an asymptomatic infection with co-infections in 14 of them (53.9%), with influenza A/parainfluenza-2 virus the major cause of co-infection (28.6%). Four of the asymptomatic patients later developed symptoms (5–14 days post testing), thus the overall incidence of symptoms associated with RVI within the first month after transplantation was 9.7% which is higher compared to other studies, probably due to the assay used. We found a high rate of RVI in asymptomatic patients not previously reported probably because most of the studies described RVI during symptomatic episodes. The primary overall etiology of RVI was influenza A (February–March), adenovirus (October), parainfluenza (March) and rhinovirus (March–April). These results are in consonance with other studies showing the highest rate of infection during February and March, with the majority of the cases associated with influenza A infection, with nearly half of them symptomatic. All patients overcome the infection in the absence of severe symptoms and did not require antiviral administration. The incidence of RVI was not associated with the type of graft (28% in renal transplants, 28.7% in liver recipients, 33.3% in heart recipients). Viral infection was significantly lower in patients receiving triple immunosuppressive therapy compared to quadruple immunosuppressive therapy (p-value = 0.044, Wilcoxon test, Table 1). In addition, we found higher rates of RVI in patients at high risk for CMV infection (CMV seronegative recipient that receives a graft from a sero-positive donor; p-value = 0.001, Wilcoxon test).

In addition to mPCR, two additional methods were used for the diagnosis of RVI, viral culture followed by mPCR for the detection of human metapneumovirus, adenovirus, coronavirus 229E/NL63 and parainfluenza 1–3, rhinovirus A/B, coronavirus–OC43/HKU1, respiratory syncytial A–B and influenza A–B and immunofluorescence (IFA, Biotrin-RV Panel, Biotrin-International Ltd.) alone for the detection of adenovirus, influenza A–B, parainfluenza 1–3 and respiratory syncytial virus (Fig. 1). Only 25/98 samples (25.5%) gave identical results using the three assays, demonstrating that mPCR detects more respiratory virus (36.1%) than culture (28.5%) and IFA (3.1%) which is in agreement with previous results.

It is important to consider RVI, especially influenza A virus in immunosuppressed patients since early antiviral therapy in symptomatic cases is associated with improved outcomes. Given the high rate of RVI, measures to avoid nosocomial transmission should be

| Table 1 |
| Patient's characteristics. |
| No. (%) |
| Total number of patients | 98 |
| Median age [IQR] | 52 (57–59.75) |
| Sex | |
| Men | 59 (60.2) |
| Women | 39 (39.8) |
| Transplant recipients | |
| Liver | 31 (31.6) |
| Kidney | 61 (62.2) |
| Heart | 6 (6.2) |
| Main cause of SOT | |
| Kidney recipients | |
| Immune disorders | 18 (29.5) |
| Congenital diseases | 17 (27.9) |
| Liver recipients | |
| Toxic–metabolic disorders | 11 (35.5) |
| Infectious diseases | 9 (29.1) |
| Heart recipients | |
| Vascular diseases | 6 (100.0) |
| Immunosuppression regimen | |
| Tacrolimus + MMF + steroids | 48 (48.9) |
| Ciclosporine + MMF + steroids | 14 (14.3) |
| Anti-CD25 + tacrolimus + MMF + steroids | 30 (30.6) |
| Thymoglobulin + tacrolimus + MMF + steroids | 6 (6.1) |
| Patients with symptoms | |
| Asymptomatic infections | 5 (5.6) |
| Asymptomatic infections that developed later symptoms | 26 (26.5) |
| Overall incidence of symptomatic RVI within one month after SOT | 4 (4.1) |
| Patients vaccinated against influenza A | 61 (62.2) |
| Vaccinated patients with influenza A symptomatic infection | 6.5%

Note: MMF, mycophenolate mofetil; SOT, solid organ transplantation; RVI, respiratory viral infections.
rigorous, with infection control measures such as patients isolation and avoidance of contact with symptomatic caregivers. Thus, it may be necessary to increase the vaccination rate among SOT candidates and also close contacts, in order to confer indirect protection for those non-responder to vaccination.

Funding

Instituto de Salud Carlos III-FIS (P06/060521 and P08/0392) and the Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (1+D+I) PI05/0226.

Conflict of interest

Authors declare no conflict of interest.

Ethical approval

The study was approved by the Virgen del Rocio University Hospital Ethical Committee.

References

1. Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther 2007;12:627–38.
2. Gerna G, Piralla A, Rovida F, Rognoni V, Marchi A, Locatelli F, et al. Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. J Med Virol 2009;81:1498–507.
3. Bonatti H, Pruett TL, Brandacher G, Hagspiel KD, Houssenni AM, Sifri CD, et al. Pneumonia in solid organ recipients: spectrum of pathogens in 217 episodes. Transplant Proc 2009;41:13.
4. Lopez-Medrano F, Aguado JM, Lizasoain M, Folgueira D, Juan RS, Díaz-Pedroche C, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation 2007;84:851–6.
5. Metzgar D, Myers CA, Russell KL, Faix D, Blair PJ, Brown J, et al. Single assay for simultaneous detection and differential identification of human and avian influenza virus types, subtypes, and emergent variants. PLoS One 2010;5:e8995.
6. Soccal PM, Aubert JD, Bridevaux PO, Garbino J, Thomas Y, Rochat T, et al. Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. Clin Infect Dis 2010;51:163–70.
7. Openshaw PJ, Tregonning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005;18:541–55.
8. McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant 2003;22:745–53.
9. Peck AJ, Englund JA, Kupfers J, Guthrie KA, Corey I, Morrow R, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007;110:1681–8.
10. Drews SJ, Blair J, Lombos E, DeLima C, Burton L, Mazzulli T, et al. Use of the Seeplex RV Detection kit for surveillance of respiratory viral outbreaks in Toronto, Ontario, Canada. Ann Clin Lab Sci 2008;38:376–9.

Omar J. BenMarzouk-Hidalgo* Jose Molina* Elisa Cordero Laura Merino
Unit of Infectious Disease, Microbiology and Preventive Medicine, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocio/CSIC/University of Sevilla, Spain

Virginia Cabello
Service of Nephrology, Hospitales Universitarios Virgen del Rocio Sevilla, Spain

Gonzalo Suarez-Artacho
Hepatobiliary and Pancreatic Surgery and Hepatic Transplant Unit, Hospitales Universitarios Virgen del Rocio Sevilla, Spain

Manuel Sobrino
Service of Cardiology, Hospitales Universitarios Virgen del Rocio Sevilla, Spain

Pilar Perez-Romero*
Unit of Infectious Disease, Microbiology and Preventive Medicine, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocio/CSIC/University of Sevilla, Avda Manuel Siurot s/n. 41013, Sevilla, Spain

* Corresponding author. Tel.: +34 955013653; fax: +34 955013292.
E-mail addresses: mariap.perez.exts@juntadeandalucia.es, pilarper@hotmail.com (P. Perez-Romero)

* These authors contributed equally to this work.

16 June 2011